3.97  -0.58 (-12.75%)		08-17 15:59
Open: 3.45 High: 4.3 Volume: 1,611,102		Pre. Close: 4.55 Low: 3.39 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	8.46	1-year :	11.24
Resists	First :	7.24	Second :	9.63
Pivot price	4.93
Supports	First :	3.39	Second :	2.82
MAs	MA(5) :	4.5	MA(20) :	5.27
	MA(100) :	12.44	MA(250) :	16.32
MACD	MACD :	-1.1	Signal :	-1.2
%K %D	K(14,3) :	11.6	D(3) :	11.8
RSI	RSI(14): 32.1
52-week	High :	59.7	Low :	3.39

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ APUS ] has closed above bottom band by 23.5%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.91 - 4.94	4.94 - 4.95
Low:	4.49 - 4.52	4.52 - 4.54
Close:	4.51 - 4.55	4.55 - 4.58

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

Fri, 14 Aug 2026
Apimeds Pharmaceuticals (APUS) flags going-concern risk amid $55M loss and debt - Stock Titan

Fri, 14 Aug 2026
Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) Share Price, APUS Stock News, APUS Share Price & Updates - kalkine.com.au

Sat, 08 Aug 2026
APUS PE Ratio & Valuation, Is APUS Overvalued - Intellectia AI

Fri, 07 Aug 2026
Apimeds Pharmaceuticals US Inc (APUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Fri, 07 Aug 2026
Apimeds Pharmaceuticals US Names Christopher Kim Chief Scientific Officer - Moomoo

Fri, 07 Aug 2026
Apimeds Pharmaceuticals appoints Dr. Christopher Kim as chief scientific officer - Investing.com Nigeria

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.